JBTM Q3 deep dive: Protein Solutions resilience offsets CPG softness, margin outlook improves

What happened

JBT Marel's Q3 2026 sales were flat at $994 million, missing analyst estimates of $1.03 billion. Adjusted profit per share was $2.19, above estimates of $2.10. Full-year revenue guidance was cut to $3.98 billion at the midpoint, while profit guidance was raised.

Confirmed

Global impact / market context

Steady profit per sale and higher profit guidance show cost control is offsetting weaker revenue. For investors, this suggests earnings can hold up even when sales disappoint, though the lower revenue outlook signals softer demand for the company's food processing and aviation equipment.

Analyst inference

The market responded positively because management stressed keeping profitability while sales were flat. A $1.52 billion backlog, meaning orders not yet delivered, gives some revenue visibility. Meanwhile, the revenue guidance cut points to softness in consumer packaged goods customers, balanced by resilience in protein solutions.

Analyst inference

What to watch

1. Full-year revenue guidance sits at $3.98 billion at the midpoint, down from $4.03 billion, and adjusted profit guidance was raised to $8.25 per share at the midpoint. Confirmed
2. Watch whether the $1.52 billion backlog converts to sales on schedule, since delays would pressure revenue and cash available, which means cash on hand to run operations. Proposed
3. Track protein solutions orders versus consumer packaged goods demand; continued weakness in consumer packaged goods could force further revenue cuts, while protein strength would support capital spending plans. Analyst inference

Evidence

• stockstory.org